<DOC>
	<DOCNO>NCT00890097</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy AL-8309B Ophthalmic Solution versus Vehicle administer topical ocular drop treatment geographic atrophy ( GA ) secondary age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Geographic Atrophy Treatment Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Willing give write informed consent , make require study visit , follow instruction . Able administer eye drop caretaker administer eye drop . Study eye : Atrophy secondary agerelated macular degeneration , best correct visual acuity ( BCVA ) 35 letter ( 20/200 Snellen equivalent ) good , clear ocular medium , adequate pupillary dilation . Other protocoldefined inclusion criterion may apply . Pregnant , nursing , use adequate contraception . Ocular disease study eye , nonexudative AMD . History cataract surgery either eye within past 3 month screen . History evidence serious ocular trauma intraocular surgery either eye within past 6 month screen . Any medical condition would make participation trial adherence study schedule difficult unlikely . Participation investigational drug device study within 30 day screen . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Geographic Atrophy</keyword>
	<keyword>GA</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>AMD</keyword>
</DOC>